Kamada Expands Biosimilar Portfolio With Commercial Launch Of Two Additional New Products In Israel, Adding To Existing Portfolio Of Two Products

Kamada Ltd. has expanded its biosimilar portfolio with the commercial launch of two new products in Israel: Ustekinumab-Kamada and Enoxaparin-Kamada, adding to its existing two biosimilars. The company anticipates its biosimilar portfolio will generate approximately $4 million in sales by 2026, increasing to $10 million by 2028, and aims to have at least 12 marketed products by 2030, potentially generating $20 million to $25 million in annual revenue. All four biosimilars are approved as interchangeable with their reference biologics.